Drug intelligence / Profile preview

small interfering RNA targeting Mic60

Development stage
Preclinical
Lead developer
The Wistar Institute
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous
01

Overview

Small interfering RNA targeting Mic60 is an experimental RNA interference (RNAi) agent designed to silence the expression of Mic60, also known as Mitofilin or IMMT. Mic60 is a critical structural component of the Mitochondrial Contact Site and Cristae Organizing System (MICOS) complex, which maintains mitochondrial cristae architecture and respiratory function. In breast cancer research, this siRNA is used as a molecular tool to investigate the consequences of Mic60 loss, which is associated with aggressive disease. Silencing Mic60 has been shown to induce the expression of epithelial-mesenchymal transition (EMT) master regulators (such as Twist, Snail, and Zeb2) and activate the NF-κB signaling pathway. This molecular reprogramming leads to increased tumor cell migration and invasion in vitro and accelerated tumor growth in vivo. While primarily used to study mitochondrial metabolic reprogramming and tumor progression, the downmodulation of Mic60 appears to promote rather than inhibit cancer aggressiveness.

Other names
Mic60 siRNAMic-60 siRNAMic 60 siRNAMitofilin siRNAIMMT siRNAsiRNA targeting Mic60
02

Targets

MIC60 (MICOS complex subunit MIC60)

Beyond the preview

Go deeper on small interfering RNA targeting Mic60.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on small interfering RNA targeting Mic60.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call